Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer.

Cho HJ, Kim SR, Kim HR, Han JO, Kim YH, Kim DK, Park SI.

Ann Thorac Surg. 2014 Jun;97(6):1920-5. doi: 10.1016/j.athoracsur.2014.03.004. Epub 2014 Apr 24.

PMID:
24768044
2.

Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.

Cerfolio RJ, Bryant AS.

Ann Thorac Surg. 2008 Aug;86(2):362-6; discussion 366-7. doi: 10.1016/j.athoracsur.2008.04.042.

PMID:
18640297
3.

Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.

Okada M, Sakamoto T, Yuki T, Mimura T, Nitanda H, Miyoshi K, Tsubota N.

J Thorac Cardiovasc Surg. 2005 Apr;129(4):825-30.

4.

Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease.

Iwasaki A, Shirakusa T, Miyoshi T, Hamada T, Enatsu S, Maekawa S, Hiratsuka M.

Thorac Cardiovasc Surg. 2006 Feb;54(1):42-6.

PMID:
16485188
5.

Surgical outcomes after initial surgery for clinical single-station N2 non-small-cell lung cancer.

Hishida T, Yoshida J, Ohe Y, Aokage K, Ishii G, Nagai K.

Jpn J Clin Oncol. 2014 Jan;44(1):85-92. doi: 10.1093/jjco/hyt164. Epub 2013 Nov 7.

PMID:
24203815
6.

The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.

Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH.

Ann Thorac Surg. 2008 Oct;86(4):1092-7. doi: 10.1016/j.athoracsur.2008.06.056.

PMID:
18805138
7.

Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2?

Rea F, Marulli G, Callegaro D, Zuin A, Gobbi T, Loy M, Sartori F.

Lung Cancer. 2004 Aug;45(2):215-20.

PMID:
15246193
8.

Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung.

Sayar A, Turna A, Kiliçgün A, Solak O, Urer N, Gürses A.

Eur J Cardiothorac Surg. 2004 Mar;25(3):434-8.

PMID:
15019674
9.

Complete thoracic mediastinal lymphadenectomy leads to a higher rate of pathologically proven N2 disease in patients with non-small cell lung cancer.

Cerfolio RJ, Bryant AS, Minnich DJ.

Ann Thorac Surg. 2012 Sep;94(3):902-6. doi: 10.1016/j.athoracsur.2012.05.034. Epub 2012 Jul 7.

PMID:
22776083
10.

Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer.

Demir A, Turna A, Kocaturk C, Gunluoglu MZ, Aydogmus U, Urer N, Bedirhan MA, Gurses A, Dincer SI.

Ann Thorac Surg. 2009 Apr;87(4):1014-22. doi: 10.1016/j.athoracsur.2008.12.053.

PMID:
19324121
11.

Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.

Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Tsuboi M; Japanese Clinical Oncology Group.

J Thorac Cardiovasc Surg. 2001 Oct;122(4):803-8.

12.

[Results of surgery for non-small cell lung cancer with N2 involvement unsuspected before thoracotomy].

Jiménez MF, Varela G, Novoa NM, Aranda JL.

Arch Bronconeumol. 2008 Feb;44(2):65-9. Spanish.

13.

Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.

Riquet M, Manac'h D, Le Pimpec-Barthes F, Dujon A, Chehab A.

Ann Thorac Surg. 1999 Jun;67(6):1572-6.

PMID:
10391257
14.

Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).

Ma Q, Liu D, Guo Y, Shi B, Song Z, Tian Y.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):342-8. doi: 10.3779/j.issn.1009-3419.2010.04.14.

15.

Surgical treatment of primary lung cancer with synchronous brain metastases.

Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC.

J Thorac Cardiovasc Surg. 2001 Sep;122(3):548-53.

16.

Clinical outcomes of thoracoscopic lobectomy for patients with clinical N0 and pathologic N2 non-small cell lung cancer.

Zhong C, Yao F, Zhao H.

Ann Thorac Surg. 2013 Mar;95(3):987-92. doi: 10.1016/j.athoracsur.2012.10.083. Epub 2012 Dec 20.

PMID:
23261117
18.

Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.

Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH; Eastern Cooperative Oncology Group.

J Thorac Cardiovasc Surg. 2004 Jul;128(1):130-7.

19.

Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved.

Matsuguma H, Nakahara R, Ishikawa Y, Suzuki H, Inoue K, Katano S, Yokoi K.

Interact Cardiovasc Thorac Surg. 2008 Aug;7(4):573-7. doi: 10.1510/icvts.2007.174342. Epub 2008 Apr 15.

PMID:
18413349
20.

Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials.

Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M; Japan Clinical Oncology Group.

Lung Cancer. 2001 Oct;34(1):29-36.

PMID:
11557110

Supplemental Content

Support Center